MAPT and mucopolysaccharidosis type 2: Whether tau aggregations exist in human MPS II brain pathological specimens remains to be determined, but this raises the possibility of using currently available tau-aggregation inhibitors to treat MPS II neurodegeneration, provided tau aggregations are proven to exist.